Last updated: 2026-10-12 22:02:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
BioMarin Pharmaceuticals Inc. (BMRN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $55.41, with a market capitalization of $10.61B and a P/E ratio of 145.37. Over the past 52 weeks, its price has ranged from $49.26 to $70.98. This page covers its latest market performance, valuation, price trends and company information.
$10.61B | |
$55.56 | |
$151.75 | |
$3.87 | |
$54.80 | |
1.93M | |
2.06M | |
145.37 | |
$70.98 | |
$49.26 | |
-- | |
-- |
BioMarin Pharmaceuticals Inc. (BMRN) is trading at $55.43 in after-hours trading as of 2026-10-12 21:49:00, up 1.16% ($0.63) from the regular-session close of $54.80.
After-hours trading shows how investors are pricing BMRN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, BioMarin Pharmaceuticals Inc. (BMRN) moved from $58.44 to $55.41, representing a decline of 5.19% ($3.03).
The stock traded between $53.90 and $60.16 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.53 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 28.3%
BMRN is currently trading at $55.41, placing it 28.3% of the way from its 52-week low of $49.26 to its 52-week high of $70.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 3221 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioMarin Pharmaceuticals Inc. (BMRN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.